Functional Dyspepsia Market Growth to Accelerate in Forecast Period , DelveInsight Analyzes Astellas Pharma, Zeria Pharmaceutical, Renexxion, RaQualia Pharma, Tsumura and Company - Barchart
| TSUA Stock | EUR 23.60 0.00 0.00% |
Slightly above 56% of Tsumura's investor base is looking to short. The analysis of current outlook of investing in Tsumura Co suggests that many traders are alarmed regarding Tsumura's prospects. Tsumura's investing sentiment can be driven by a variety of factors including economic data, Tsumura's earnings reports, geopolitical events, and overall market trends.
Tsumura |
Functional Dyspepsia Market Growth to Accelerate in Forecast Period , DelveInsight Analyzes Astellas Pharma, Zeria Pharmaceutical, Renexxion, RaQualia Pharma, Tsumura and Company Barchart
Read at news.google.com
 |
Tsumura Fundamental Analysis
We analyze Tsumura's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Tsumura using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Tsumura based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Gross Profit
Gross Profit Comparative Analysis
Tsumura is rated second in gross profit category among its peers. Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.
Tsumura Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Tsumura stock to make a market-neutral strategy. Peer analysis of Tsumura could also be used in its relative valuation, which is a method of valuing Tsumura by comparing valuation metrics with similar companies.
Peers
Tsumura Related Equities
| LDZU | ASPEN PHARUNADR | 4.68 | ||||
| TSUA | Tsumura | 0.00 | ||||
| CJH | CanSino Biologics | 0.55 | ||||
| TKDA | Takeda Pharmaceutical | 0.81 | ||||
| GU5 | Guangzhou Baiyunshan | 0.93 | ||||
| MRK | Merck | 1.16 | ||||
| HPX | Hisamitsu Pharmaceutical | 1.59 | ||||
| 5EA | Elanco Animal | 1.60 | ||||
| 3KY | HANSOH PHARMAC | 2.70 |
Additional Tools for Tsumura Stock Analysis
When running Tsumura's price analysis, check to measure Tsumura's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tsumura is operating at the current time. Most of Tsumura's value examination focuses on studying past and present price action to predict the probability of Tsumura's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tsumura's price. Additionally, you may evaluate how the addition of Tsumura to your portfolios can decrease your overall portfolio volatility.